193 related articles for article (PubMed ID: 26711323)
1. Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues.
Fletcher P; Herrera C; Armanasco N; Nuttall J; Shattock RJ
AIDS Res Hum Retroviruses; 2016 Apr; 32(4):334-8. PubMed ID: 26711323
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention.
Dezzutti CS; Yandura S; Wang L; Moncla B; Teeple EA; Devlin B; Nuttall J; Brown ER; Rohan LC
Pharm Res; 2015 Nov; 32(11):3768-81. PubMed ID: 26078001
[TBL] [Abstract][Full Text] [Related]
3. Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates.
Herrera C; Armanasco N; García-Pérez J; Ziprin P; Olejniczak N; Alcamí J; Nuttall J; Shattock RJ
AIDS; 2016 Apr; 30(7):1015-25. PubMed ID: 26854808
[TBL] [Abstract][Full Text] [Related]
4. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Veselinovic M; Yang KH; LeCureux J; Sykes C; Remling-Mulder L; Kashuba ADM; Akkina R
Virology; 2014 Sep; 464-465():253-263. PubMed ID: 25105490
[TBL] [Abstract][Full Text] [Related]
5. Preclinical discovery and development of maraviroc for the treatment of HIV.
Veljkovic N; Vucicevic J; Tassini S; Glisic S; Veljkovic V; Radi M
Expert Opin Drug Discov; 2015 Jun; 10(6):671-84. PubMed ID: 25927601
[TBL] [Abstract][Full Text] [Related]
6. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
[TBL] [Abstract][Full Text] [Related]
7. Models for predicting effective HIV chemoprevention in women.
Nicol MR; Emerson CW; Prince HM; Nelson JA; Fedoriw Y; Sykes C; Geller EJ; Patterson KB; Cohen MS; Kashuba AD
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):369-76. PubMed ID: 25501616
[TBL] [Abstract][Full Text] [Related]
8. Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers.
Coll J; Moltó J; Boix J; Gómez-Mora E; Else L; García E; Paredes R; Ouchi D; Carrillo A; Escrig R; Back D; Clotet B; Cabrera C
AIDS; 2015 Oct; 29(16):2149-54. PubMed ID: 26544579
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological profile and clinical findings of Maraviroc (Celsentri® Tablets)].
Hizue M
Nihon Yakurigaku Zasshi; 2010 Dec; 136(6):349-58. PubMed ID: 21139287
[No Abstract] [Full Text] [Related]
10. Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.
Ramanathan R; Jiang Y; Read B; Golan-Paz S; Woodrow KA
Acta Biomater; 2016 May; 36():122-31. PubMed ID: 26947382
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients.
van Lelyveld SF; Symons J; van Ham P; Connell BJ; Nijhuis M; Wensing AM; Hoepelman AI
Int J Antimicrob Agents; 2016 Jan; 47(1):84-90. PubMed ID: 26585497
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.
Rosario MC; Poland B; Sullivan J; Westby M; van der Ryst E
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):183-91. PubMed ID: 16639345
[TBL] [Abstract][Full Text] [Related]
13. No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy.
Raymond S; Nicot F; Carcenac R; Jeanne N; Cazabat M; Requena M; Cuzin L; Delobel P; Izopet J;
AIDS; 2016 Mar; 30(6):965-8. PubMed ID: 26752281
[TBL] [Abstract][Full Text] [Related]
14. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
15. HIV-2 susceptibility to entry inhibitors.
Borrego P; Taveira N
AIDS Rev; 2013; 15(1):49-61. PubMed ID: 23449229
[TBL] [Abstract][Full Text] [Related]
16. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
Vitiello P; Brudney D; MacCartney M; Garcia A; Smith C; Marshall N; Johnson M; Geretti AM
Intervirology; 2012; 55(2):172-8. PubMed ID: 22286889
[TBL] [Abstract][Full Text] [Related]
17. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
18. Long-term maraviroc use as salvage therapy in HIV-2 infection.
Caixas U; Ferreira J; Marinho AT; Faustino I; Grilo NM; Lampreia F; Germano I; Monteiro EC; Pereira SA
J Antimicrob Chemother; 2012 Oct; 67(10):2538-9. PubMed ID: 22729923
[No Abstract] [Full Text] [Related]
19. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
Nozza S; Galli L; Antinori A; Chiappetta S; Mazzotta F; Zaccarelli M; Ottou S; De Battista D; Pogliaghi M; Di Pietro M; Malnati M; Ripa M; Bonora S; Lazzarin A;
Clin Microbiol Infect; 2015 May; 21(5):510.e1-9. PubMed ID: 25656621
[TBL] [Abstract][Full Text] [Related]
20. [Utilizing the potential of maraviroc early. "Clear in second line therapy" (interview by Dr. Felicitas Zorn)].
van Lunzen J
MMW Fortschr Med; 2011 May; 153(18):31. PubMed ID: 21604591
[No Abstract] [Full Text] [Related]
[Next] [New Search]
